Klotho Neurosciences, Inc. (KLTO)
Official siteBIOTECHNOLOGY
Last updated: Jul 08, 2026 at 5:00 PM ET
Klotho Neurosciences, Inc. (KLTO) Financials: Revenue, Profit and Cash Flow
Klotho Neurosciences reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$10.55M and operating cash flow was -$5.89M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$13.64M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $7.15M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0 | N/A | N/A | N/A | N/A |
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | N/A | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
| Research and development | $634.19K | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$7.15M | -$5.54M | -$631.32K | -$657.02K | -$1.11M | -$913.15K |
| Net income | -$10.55M | -$6.15M | -$707.46K | $1.23M | -$1.11M | -$913 |
| EBITDA | N/A | N/A | -$631.24K | -$101.10K | -$1.11M | N/A |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$12.41M | -$5.49M | -$9.51M | -$1.81M | -$1.85M | -$1.89M | -$1.59M | -$1.60M | -$2.87M | -$395.61K | -$672.04K | $62.42K |
| Net income | -$13.64M | -$3.69M | -$13.86M | -$1.45M | -$2.90M | -$4.09M | -$2.12M | -$2.07M | -$2.96M | -$451.64K | -$672.04K | -$1.42M |
Balance Sheet
As of Dec 2025, cash and equivalents of $7.18M were 74.9% of total assets of $9.59M, against total liabilities of $129.76K.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
| Total assets | $9.59M | $2.46M | $2.19M | $118.25M | $4.95K | $1.07M |
| Current assets | $7.29M | $157.81K | $6.65K | $440.16K | $4.95K | $334.87K |
| Cash and equivalents | $7.18M | $63.74K | $2.81K | $340.96K | $4.95K | $334.87K |
| Total liabilities | $129.76K | $1.27M | $1.62M | $4.93M | $8.51K | N/A |
| Short-term debt | N/A | $240.75K | $1.63M | $1.35M | N/A | N/A |
| Shareholder equity | $9.46M | $1.19M | $571.72K | -$4.04M | -$3.56K | N/A |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $137.69M | $65.01M | $59.74M | $9.59M | $10.07M | $10.85M | $2.99M | $2.46M | $2.46M | $3.31M | $19.59M | $2.19M |
| Total liabilities | $1.35M | $7.11M | $8.27M | $129.76K | $145.89K | $195.41K | $2.35M | $1.27M | $1.00M | $4.86M | $8.50M | $1.62M |
| Cash and equivalents | $57.39M | $9.34M | $10.00M | $7.18M | $7.35M | $8.43M | $565.87K | $63.74K | $50.90K | $845.34K | $8.05K | $2.81K |
| Shareholder equity | $136.35M | $57.90M | $51.47M | $9.46M | $9.93M | $10.65M | $638.71K | $1.19M | $1.46M | -$1.55M | -$7.73M | $571.72K |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$5.89M | -$2.95M | -$446.92K | -$493.04K | -$284.02K | -$165.13K |
| Capital expenditures | N/A | $123.50K | $13.89K | $125.41K | $0 | $0 |
| Free cash flow | N/A | -$3.07M | -$460.80K | -$618.45K | -$284.02K | -$165.13K |
| Dividends paid | $0 | $120.00K | N/A | N/A | N/A | N/A |
| Investing cash flow | $0 | -$123.50K | $23.85K | -$116.15M | N/A | N/A |
| Financing cash flow | $13.00M | $3.13M | $350.00K | $116.98M | $250.00K | $500.00K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.41M | -$6.85M | -$4.97M | -$1.28M | -$1.12M | -$1.94M | -$1.55M | -$944.15K | -$1.07M | -$907.42K | -$21.98K | -$199.51K |
| Capital expenditures | $20.61M | N/A | N/A | N/A | $0 | $1 | $0 | $4 | $0 | $3 | $123.50K | $0 |
| Free cash flow | -$31.01M | N/A | N/A | N/A | -$1.12M | -$1.94M | -$1.55M | -$944.16K | -$1.07M | -$907.43K | -$145.47K | -$199.51K |
Frequently Asked Questions About KLTO
What is Klotho Neurosciences' annual revenue?
Klotho Neurosciences reported revenue of $0 for the fiscal year ended Dec 31, 2025.
Is Klotho Neurosciences profitable?
No. Klotho Neurosciences reported net income of -$10.55M for the fiscal year ended Dec 31, 2025.
How much debt does Klotho Neurosciences have?
The balance sheet dated Dec 31, 2025 reported cash and equivalents of $7.18M.
KLTO pages: Overview, Financials